Patents by Inventor Andreas Fisch
Andreas Fisch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11203595Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: July 28, 2020Date of Patent: December 21, 2021Assignee: NOVARTIS AGInventors: Badry Bursulaya, Andreas Fisch, James Paul Lajiness, Rainer Machauer, Swapnil Malekar, Hank Michael James Petrassi, Farshad Ramazani, Anne-Catherine Remond, Thomas Ullrich, Peggy Usselmann, Eric Vangrevelinghe
-
Publication number: 20210188842Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: July 28, 2020Publication date: June 24, 2021Inventors: Badry BURSULAYA, Andreas FISCH, James Paul LAJINESS, Rainer MACHAUER, Swapnil MALEKAR, Hank Michael James PETRASSI, Farshad RAMAZANI, Anne-Catherine REMOND, Thomas ULLRICH, Peggy USSELMANN, Eric VANGREVELINGHE
-
Publication number: 20210177824Abstract: The present invention relates to a pharmaceutical composition comprising an aqueous suspension of: (i) crystalline N-(3,4-dichlorophenyl)-3-(pyridin-4-yl)-7-oxabicyclo[2.2.1]heptane-2-carboxamide or a pharmaceutically acceptable salt thereof; and (ii) a surfactant comprising a water-soluble co-polymer characterized by >5% solubility in water at 25° C. The compositions provide extended release of N-(3,4-dichlorophenyl)-3-(pyridin-4-yl)-7-oxabicyclo[2.2.1] heptane-2-carboxamide, and are suitable for intra-articular injection to a joint of a patient suffering from arthritis, joint injury or cartilage injury.Type: ApplicationFiled: November 8, 2018Publication date: June 17, 2021Inventors: Carlo Castagnoli, Andreas Fisch, Mathilde Lorscheider, Manjali Laxman Neharkar, Bernd Ulrich Riebesehl
-
Patent number: 10919887Abstract: The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.Type: GrantFiled: September 20, 2016Date of Patent: February 16, 2021Assignee: Novartis AGInventors: Eric Aubin, Anthony Casarez, Andreas Fisch, Zaixing Li, Mika Lindvall, Heinz Ernst Moser, Michael Mutz, Folkert Reck, Bernd Ulrich Riebesehl, Marc Schoenhentz, Vijay Sethuraman, Robert Lowell Simmons
-
Patent number: 10766894Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: September 21, 2017Date of Patent: September 8, 2020Assignee: NOVARTIS AGInventors: Badry Bursulaya, Andreas Fisch, James Paul Lajiness, Rainer Machauer, Swapnil Malekar, Hank Michael James Petrassi, Farshad Ramazani, Anne-Catherine Remond, Thomas Ullrich, Peggy Usselmann, Eric Vangrevelinghe
-
Publication number: 20190300522Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: September 21, 2017Publication date: October 3, 2019Inventors: Badry BURSULAYA, Andreas FISCH, James Paul LAJINESS, Rainer MACHAUER, Swapnil MALEKAR, Hank Michael James PETRASSI, Farshad RAMAZANI, Anne-Catherine REMOND, Thomas ULLRICH, Peggy USSELMANN, Eric VANGREVELINGHE
-
Patent number: 10112907Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: September 21, 2017Date of Patent: October 30, 2018Assignee: NOVARTIS AGInventors: Badry Bursulaya, Andreas Fisch, James Paul Lajiness, Rainer Machauer, Swapnil Malekar, Hank Michael James Petrassi, Farshad Ramazani, Anne-Catherine Remond, Thomas Ullrich, Peggy Usselmann, Eric Vangrevelinghe
-
Publication number: 20180273522Abstract: The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.Type: ApplicationFiled: September 20, 2016Publication date: September 27, 2018Inventors: Eric AUBIN, Anthony CASAREZ, Andreas FISCH, Zaixing LI, Mika LINDVALL, Heinz Ernst MOSER, Michael MUTZ, Folkert RECK, Bernd Ulrich RIEBESEHL, Marc SCHOENHENTZ, Vijay SETHURAMAN, Robert Lowell SIMMONS
-
Publication number: 20180086716Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: September 21, 2017Publication date: March 29, 2018Inventors: Badry BURSULAYA, Andreas FISCH, James Paul LAJINESS, Rainer MACHAUER, Swapnil MALEKAR, Hank Michael James PETRASSI, Farshad RAMAZANI, Anne-Catherine REMOND, Thomas ULLRICH, Peggy USSELMANN, Eric VANGREVELINGHE
-
Patent number: 8569480Abstract: Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining normovolemia and/or for improving the macro- and microcirculation and/or for improving the nutritive oxygen supply and/or for stabilizing hemodynamics and/or for improving the volume efficiency and/or for reducing the plasma viscosity and/or for increasing anemia tolerance and/or for hemodilution, especially for therapeutic hemodilution in disturbed blood supply and arterial, especially peripheral arterial, occlusive diseases.Type: GrantFiled: August 4, 2010Date of Patent: October 29, 2013Assignee: B. Braun Melsungen AGInventors: Michael Boll, Andreas Fisch, Donat R. Spahn
-
Patent number: 7863260Abstract: Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining normovolemia and/or for improving the macro- and microcirculation and/or for improving the nutritive oxygen supply and/or for stabilizing hemodynamics and/or for improving the volume efficiency and/or for reducing the plasma viscosity and/or for increasing anemia tolerance and/or for hemodilution, especially for therapeutic hemodilution in disturbed blood supply and arterial, especially peripheral arterial, occlusive diseases.Type: GrantFiled: March 1, 2005Date of Patent: January 4, 2011Assignee: B. Braun Melsungen AGInventors: Michael Boll, Andreas Fisch, Donat R. Spahn
-
Publication number: 20100298266Abstract: Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining normovolemia and/or for improving the macro- and microcirculation and/or for improving the nutritive oxygen supply and/or for stabilizing hemodynamics and/or for improving the volume efficiency and/or for reducing the plasma viscosity and/or for increasing anemia tolerance and/or for hemodilution, especially for therapeutic hemodilution in disturbed blood supply and arterial, especially peripheral arterial, occlusive diseases.Type: ApplicationFiled: August 4, 2010Publication date: November 25, 2010Inventors: Michael Boll, Andreas Fisch, Donat R. Spahn
-
Publication number: 20070282014Abstract: Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining normovolemia and/or for improving the macro- and microcirculation and/or for improving the nutritive oxygen supply and/or for stabilizing hemodynamics and/or for improving the volume efficiency and/or for reducing the plasma viscosity and/or for increasing anemia tolerance and/or for hemodilution, especially for therapeutic hemodilution in disturbed blood supply and arterial, especially peripheral arterial, occlusive diseases.Type: ApplicationFiled: March 1, 2005Publication date: December 6, 2007Inventors: Michael Boll, Andreas Fisch, Donat Spahn
-
Patent number: 7220569Abstract: Nucleic acids encoding factor X analogues are provided that have a modification in the region of the natural Factor Xa activation cleavage site. The modification results in a processing site for a protease not naturally cleaving in this region of the Factor X sequence.Type: GrantFiled: April 4, 2003Date of Patent: May 22, 2007Assignee: Baxter AktiengesellschaftInventors: Michele Himmelspach, Uwe Schlokat, Friedrich Dorner, Andreas Fisch, Johann Eibl
-
Publication number: 20030181381Abstract: Factor X analogues having a modification in the region of the natural Factor Xa activation cleavage site, said modification representing a processing site of a protease not naturally cleaving in this region of the Factor X sequence, preparations containing the Factor X analogues according to the invention, and processes for the preparation thereof are described.Type: ApplicationFiled: April 4, 2003Publication date: September 25, 2003Inventors: Michele Himmelspach, Uwe Schlokat, Friedrich Dorner, Andreas Fisch, Johann Eibl
-
Patent number: 6573071Abstract: Factor X analogues having a modification in the region of the natural Factor Xa activation cleavage site, said modification representing a processing site of a protease not naturally cleaving in this region of the Factor X sequence, preparations containing the Factor X analogues according to the invention, and processes for the preparation thereof are described.Type: GrantFiled: November 12, 1999Date of Patent: June 3, 2003Assignee: Baxter AktiengesellschaftInventors: Michele Himmelspach, Uwe Schlokat, Friedrich Dorner, Andreas Fisch, Johann Eibl